# Rakuten Medical

> Global biotechnology company (founded 2010 in San Diego, California as Aspyrian Therapeutics,
> renamed after investment from Rakuten Group) developing precision, cell-targeting investigational
> cancer therapies on its Alluminox platform — a drug-device combination pairing an IRDye 700DX
> light-activated dye conjugated to a cell-targeting antibody with local 690nm red-light illumination.
> Lead asset ASP-1929 (EGFR-targeting antibody-dye conjugate) is approved in Japan as Akalux for
> unresectable locally advanced or recurrent head and neck cancer and is in global Phase 3 development.
> Rakuten Medical publishes no public API, developer portal, SDK, or machine-readable specification.
> This file was generated by API Evangelist from the public website; it is not published by
> Rakuten Medical.

Generated: 2026-08-05
Method: generated (from apis.yml + probed public pages)
Source: https://rakuten-med.com/us/

## Company

- [Rakuten Medical](https://rakuten-med.com/us/): Company home (US locale).
- [About](https://rakuten-med.com/us/about/): History, mission, and global footprint (US, Japan, Taiwan, Switzerland, India).
- [Letter from the CEO](https://rakuten-med.com/us/about/letter/): Leadership perspective.
- [Locations](https://rakuten-med.com/us/about/location/): Office locations.
- [Careers](https://rakuten-med.com/us/recruitment/): Open roles.
- [Rakuten Medical Japan](https://rakuten-med.com/jp/): Japanese locale of the corporate site.

## Science and pipeline

- [Alluminox platform](https://rakuten-med.com/us/alluminox/): Drug-device photoimmunotherapy platform; IRDye 700DX conjugate activated by 690nm red light.
- [Pipeline](https://rakuten-med.com/us/pipeline/): ASP-1929 (approved in Japan as Akalux; global Phase 3 alone and with anti-PD-1), RM-1995 (Phase 1, Japan), RM-0256 (preclinical/trial-ready, Japan).
- [Expanded Access Policy](https://rakuten-med.com/us/pipeline/eap/): Policy on access to investigational therapies outside clinical trials.

## News

- [News](https://rakuten-med.com/us/news/): News hub.
- [Press releases](https://rakuten-med.com/us/news/press-releases/): Corporate and clinical announcements.
- [Stories](https://rakuten-med.com/us/news/stories/): Longer-form features.
- [Events](https://rakuten-med.com/us/events/): Conference and investor appearances.
- [RSS feed](https://rakuten-med.com/us/feed/): Site feed.
- [Press release RSS feed](https://rakuten-med.com/us/news/press-releases/feed/): Press-release feed.

## Contact and policy

- [Contact](https://rakuten-med.com/us/contact/): Contact routing.
- [Medical information](https://rakuten-med.com/us/contact/medical/): Healthcare-professional medical-information inquiries.
- [Business development](https://rakuten-med.com/us/contact/bd/): Partnering inquiries.
- [Media](https://rakuten-med.com/us/contact/media/): Press inquiries.
- [Privacy Policy](https://rakuten-med.com/us/privacy-policy/)
- [LinkedIn](https://www.linkedin.com/company/rakuten-medical/)

## API surface

There is none, and this is a factual observation rather than an omission. Probed 2026-08-05:
`/.well-known/security.txt`, `/.well-known/openid-configuration`, `/.well-known/oauth-authorization-server`,
`/.well-known/oauth-protected-resource`, `/.well-known/api-catalog`, `/.well-known/ai-plugin.json`,
`/.well-known/agent-card.json`, `/.well-known/agent.json`, `/llms.txt`, `/openapi.json`, `/openapi.yaml`,
`/swagger.json`, `/api-docs`, `/docs`, `/developers`, `/developer` and `/api` all returned 404 on
rakuten-med.com. No api./developer./developers./docs./mcp./status./security. subdomain resolves in DNS.
`portal.rakuten-med.com` is an F5 BIG-IP APM employee remote-access portal, not a developer portal.

- [Well-known probe record](https://raw.githubusercontent.com/api-evangelist/rakuten-medical/refs/heads/main/well-known/rakuten-medical-well-known.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/rakuten-medical/refs/heads/main/security/rakuten-medical-domain-security.yml)